GBT Announces New Employment Inducement Grants
June 02 2022 - 4:05PM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced
that on June 1, 2022, the compensation committee of GBT’s
board of directors granted 10 new employees restricted stock
units for an aggregate of 33,700 shares of the company’s common
stock. These awards were made under GBT’s Amended and Restated 2017
Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement
material to the employees entering into employment with the company
in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted
pursuant to the terms of the Plan. The Plan was adopted by GBT’s
board of directors in January 2017 and has been amended and
restated from time to time.
About Global Blood TherapeuticsGlobal Blood
Therapeutics (GBT) is a biopharmaceutical company dedicated to the
discovery, development and delivery of life-changing treatments
that provide hope to underserved patient communities, starting with
sickle cell disease (SCD). Founded in 2011, GBT is delivering on
its goal to transform the treatment and care of SCD, a lifelong,
devastating inherited blood disorder. The company has introduced
Oxbryta® (voxelotor), the first FDA-approved medicine that directly
inhibits sickle hemoglobin (HbS) polymerization, the root cause of
red blood cell sickling in SCD. GBT is also advancing its pipeline
program in SCD with inclacumab, a P-selectin inhibitor in Phase 3
development to address pain crises associated with the disease, and
GBT021601 (GBT601), the company’s next generation HbS
polymerization inhibitor. In addition, GBT’s drug discovery teams
are working on new targets to develop the next generation of
treatments for SCD. To learn more, please visit www.gbt.com and
follow the company on Twitter @GBT_news.
Contact:Steven Immergut
(media)650-410-3258simmergut@gbt.com
Courtney Roberts (investors)650-351-7881croberts@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Oct 2023 to Oct 2024